Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen

Hobohm, Carsten; Laignel, Félix; Kacza, Johannes; Küppers-Tiedt, Lea; Heindl, Mario; Schneider, Dietmar; Grosche, Jens; Härtig, Wolfgang; Michalski, Dominik

doi:10.1016/j.brainres.2011.08.024

Cited by 5 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2012, the stroke academic industry roundtable suggested beneficial assessment of (1) neuroprotective agents, (2) IV-tPA, and (3) emerging treatments to decrease reperfusion damage. [12345678910111213141516171819202122232425262728293031] Henninger and Fisher reported that <10% of all patients with AIS receive intravenous thrombolysis and it has been expected that only around 7%–15% of AIS patients are qualified for acute endovascular intervention. [29]…”

Section: Discussionmentioning

confidence: 99%

“…[12] In fact, acute focal cerebral ischemia and sequential dynamism disaster are convoyed by neuronal death in the parts of brain that cerebral blood flow was reduced. [1234]…”

Section: Introductionmentioning

confidence: 99%

“…[24] Up-to-date epidemiological studies specified that 16.9 million people suffer from stroke each year, which indicates a global incidence of 258/100,000 in each year. However, the number of survivors almost doubled among 1990 and 2010, but there are 5.9 million stroke-associated decreases globally each year.…”

Section: Introductionmentioning

confidence: 99%

“…However, the number of survivors almost doubled among 1990 and 2010, but there are 5.9 million stroke-associated decreases globally each year. [23] Death related to stroke excessively affects blacks, and this inequality is established across all categories of stroke. [5] Age and stroke severity are the main factors of outcomes.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

et al. 2017

View full text Add to dashboard Cite

Background:According to previous publications, in patients with acute ischemic cerebral infarction, thrombolytic therapy using intravenous tissue plasminogen activator (IV-tPA) necessitates precise documentation of symptoms’ onset. The aim of this study was to identify major barriers related to the IV-tPA injection in such patients.Materials and Methods:Between the year 2014-2015, patients with definitive diagnosis of acute cerebral infarction (n = 180) who attended the neurology ward located at the Isfahan Alzahra Hospital were studied. To investigate barriers related to door to IV-tPA needle time, personal reasons, and criteria for inclusion or exclusion of patients, three questionnaire forms were designed based on the Food and Drug Administration-approved indications or contraindications.Results:The mean age of males versus females was 60 versus 77.5 years (ranged 23–93 vs. 29–70 years), respectively. Out of total population, only 10.7% transferred to hospital in <4.5 h after the onset of symptoms. Regarding to eligibility for IV-tPA, 68.9% of total population have had criteria for such treatment. Concerning to both items such as transferring to hospital in <4.5 h after the onset of symptoms and eligibility for IV-tPA, only 6.6% of total population met the criteria for such management. There was ignorance or inattention to symptoms in 75% of population studied. There was a mean of 195.92 ± 6.65 min (182.8–209.04 min) for door to IV-tPA needle time.Conclusion:Despite the international guidelines for IV-tPA injection within 3–4.5 h of ischemic stroke symptoms’ onset, the results of this study revealed that falling time due to ignorance of symptoms, literacy, and living alone might need further attention. As a result, to decrease death and disability, educational programs related to the symptoms’ onset by consultant neurologist in Isfahan/Iran seem to be advantageous.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[12] In fact, acute focal cerebral ischemia and sequential dynamism disaster are convoyed by neuronal death in the parts of brain that cerebral blood flow was reduced. [1234]…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Besides, only 60-minute HBOT was applied. And the number of reduced NeuN-positive cells alone was not adequate for differentiation neuron loss from apoptosis and necrosis in those regions 37. They also found that the administration of r-tPA with HBOT decreased the macrophage-like cell accumulation at days 14 and 28 post ischemia.…”

Section: Long-term Effects Of Co-administration Of Hbot and R-tpamentioning

confidence: 99%

Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection

Yang

2017

Med Gas Res

View full text Add to dashboard Cite

Intravenous recombinant tissue-type plasminogen activator (r-tPA, alteplase) remains the recommended therapy for acute ischemic stroke. However, several factors are limiting its practical use. It makes it urgent for us to search more efficient strategies that can save the ischemic neurons, and safely extend the time window, while in the mean time reducing the detrimental effects for stroke thrombolysis. Hyperbaric oxygen therapy (HBOT) is considered to be potentially neuroprotective. Co-administration of r-tPA and HBOT has already been proved to be effective, safe and feasible in myocardial infarction. In this article, we would like to review whether HBOT has any beneficial effects on r-tPA thrombolysis. If there is, what is the underlying possible mechanisms and how to optimize for maximal effects?

show abstract

The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion

Thiankhaw

Chattipakorn

2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Middle cerebral artery occlusion (MCAO) causes focal cerebral hypoperfusion, resulting in cerebral ischemia or ischemic stroke. The main therapeutic approach is to restore an adequate blood flow to the brain via the process of reperfusion. However, rapid reperfusion can itself aggravate brain damage; this adverse effect is known as ischemic/reperfusion (I/R) injury. The pathological conditions that occur after cerebral ischemia and cerebral I/R are microvascular injury, blood-brain barrier dysfunction, post-ischemic inflammation, increased oxidative stress/reactive oxygen species, and a reduction in neuronal survival, leading to brain infarction. Animal and

show abstract

Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen

Cited by 5 publications

References 106 publications

Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection

The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion

Contact Info

Product

Resources

About